With FDA clearance imminent, Petrovic says Insulet’s latest device offers real change in diabetes care. Faced with either a bulky insulin pump or delivering multiple daily injections, Boston-based entrepreneur and venture capitalist John Brooks III sought an easier way to treat his young son’s newly diagnosed type 1 diabetes. He assembled a team of engineers […]
Patient Monitoring
Metabolic disease reversal tech company Twin Health raises $140M Series C
Twin Health announced that it raised $140 million in a Series C financing round as it scales its service in the U.S. and globally. Mountain View, California-based Twin Health develops the Whole Body Digital Twin platform designed to help reverse and prevent chronic metabolic diseases while improving energy and health. According to a news release, […]
Insulet reports positive study results for Omnipod 5
Insulet (NSDQ:PODD) last week presented positive pivotal trial data for its Omnipod 5 automated insulin delivery system. Acton, Massachusetts-based Insulet’s Omnipod 5 — which it touts as the world’s first tubeless wearable system for continuously adapting insulin delivery based on glucose levels and trends — significantly improved time in range and reduced HbA1c in the […]
Welldoc wins expanded FDA clearance for BlueStar insulin dosing platform
Welldoc announced today that it received another FDA 510(k) clearance for its BlueStar diabetes treatment platform. Columbia, Maryland-based Welldoc’s new clearance for BlueStar — the ninth in total — expands insulin dosing support to most types of insulin, including bolus and premixed insulin titration for type 2 diabetes. Previous FDA clearances include in June 2020 […]
Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of […]
Better Therapeutics expects $113M SPAC merger to go through in October
Better Therapeutics announced today that it expects its merger with Mountain Crest Acquisition Corp to close next month. San Francisco-based Better Therapeutics announced its intention to merge with Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), in April. At the time of the announcement, the companies expected the merger to be completed some time […]
Ultrahuman raises $17.5M Series B for wearable glucose monitoring tech
Ultrahuman announced today that it raised $17.5 million in a Series B financing round for its wearable glucose tracking technology. Bangalore, India-based Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes track blood glucose in real-time and optimize their diet and exercise. The platform goes beyond traditional markers like […]
FDA clears Abbott’s iPhone app for FreeStyle Libre 2
Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones. The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor […]
Dexcom beats Street — but remains coy on U.S. G7 launch
Dexcom (NSDQ:DXCM) shares are up more than 13% today — a day after Q2 results that topped the consensus forecast. The San Diego-based continuous glucose monitor developer also announced continued clinical and regulatory progress with its next-gen G7, though the timing of a U.S. G7 release is still an open question. Dexcom posted profits of […]
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward […]